3D Molecular Descriptors Important for Clinical Success

The pharmacokinetic and safety profiles of clinical drug candidates are greatly influenced by their requisite physicochemical properties. In particular, it has been shown that 2D molecular descriptors such as fraction of Sp3 carbon atoms (Fsp3) and number of stereo centers correlate with clinical success. Using the proteomic off-target hit rate of nicotinic ligands, we found that shape-based 3D descriptors such as the radius of gyration and shadow indices discriminate off-target promiscuity better than do Fsp3 and the number of stereo centers. We have deduced the relevant descriptor values required for a ligand to be nonpromiscuous. Investigating the MDL Drug Data Report (MDDR) database as compounds move from the preclinical stage toward the market, we have found that these shape-based 3D descriptors predict clinical success of compounds at preclinical and phase1 stages vs compounds withdrawn from the market better than do Fsp3 and LogD. Further, these computed 3D molecular descriptors correlate well with experimentally observed solubility, which is among well-known physicochemical properties that drive clinical success. We also found that about 84% of launched drugs satisfy either Shadow index or Fsp3 criteria, whereas withdrawn and discontinued compounds fail to meet the same criteria. Our studies suggest that spherical compounds (rather than their elongated counterparts) with a minimal number of aromatic rings may exhibit a high propensity to advance from clinical trials to market.

[1]  Peter C. Jurs,et al.  Descriptions of molecular shape applied in studies of structure/activity and structure/property relationships , 1987 .

[2]  M. Hahn Receptor surface models. 1. Definition and construction. , 1995, Journal of medicinal chemistry.

[3]  T. Halgren MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[4]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[5]  John D. Storey A direct approach to false discovery rates , 2002 .

[6]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[7]  J. Schmitt,et al.  Targeting neuronal nicotinic receptors: a path to new therapies. , 2002, Current drug targets. CNS and neurological disorders.

[8]  Brian K Shoichet,et al.  Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.

[9]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery. 4. Prediction of Aqueous Solubility Based on Atom Contribution Approach , 2004, J. Chem. Inf. Model..

[10]  S. R. Breining Recent developments in the synthesis of nicotinic acetylcholine receptor ligands. , 2004, Current topics in medicinal chemistry.

[11]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[12]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[13]  Charles Kung,et al.  Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[15]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[16]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[17]  A. Mazurov,et al.  2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands , 2005 .

[18]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[19]  Brian K Shoichet,et al.  Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. , 2006, Journal of medicinal chemistry.

[20]  A. Mazurov,et al.  Selective α7 Nicotinic Acetylcholine Receptor Ligands , 2006 .

[21]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[22]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[23]  Sanjivanjit K. Bhal,et al.  The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. , 2007, Molecular pharmaceutics.

[24]  M. Romanelli,et al.  Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential , 2007, ChemMedChem.

[25]  M. Bencherif,et al.  Nicotinic receptors as targets for therapeutic discovery , 2007, Expert opinion on drug discovery.

[26]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.

[27]  Clemencia Pinilla,et al.  A Similarity‐based Data‐fusion Approach to the Visual Characterization and Comparison of Compound Databases , 2007, Chemical biology & drug design.

[28]  Jean M. Severin,et al.  Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. , 2007, Chemical research in toxicology.

[29]  Jeffrey R. Huth,et al.  Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups , 2007, J. Comput. Aided Mol. Des..

[30]  W. S. Caldwell,et al.  Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands. , 2008, The Journal of organic chemistry.

[31]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[32]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[33]  K. Azzaoui,et al.  In vitro safety pharmacology profiling: what else beyond hERG? , 2009, Future medicinal chemistry.

[34]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[35]  J. Peters,et al.  Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.

[36]  Antoine Taly,et al.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system , 2009, Nature Reviews Drug Discovery.

[37]  L. Price,et al.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature , 2010, Psychopharmacology.

[38]  Stuart L. Schreiber,et al.  Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.

[39]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[40]  David DeCaprio,et al.  Cheminformatics approaches to analyze diversity in compound screening libraries. , 2010, Current opinion in chemical biology.

[41]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[42]  Stuart L. Schreiber,et al.  Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections , 2011, Proceedings of the National Academy of Sciences.

[43]  Ajay N. Jain,et al.  Chemical structural novelty: on-targets and off-targets. , 2011, Journal of medicinal chemistry.

[44]  N. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[45]  D. Kombo,et al.  Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. , 2012, Journal of medicinal chemistry.

[46]  Wolfgang Guba,et al.  Can we discover pharmacological promiscuity early in the drug discovery process? , 2012, Drug discovery today.

[47]  Gary Maurice Dull,et al.  Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders. , 2012, Journal of medicinal chemistry.